Value of length maze arms (in centimeters), as part of Elevated Plus Maze test
Registration Status:
Qualified
Permissible Values:
Data Type:
Number
Unit of Measure:
cm
Ids:
Value
Code Name
Code
Code System
Code Description
Designations:
Designation:
Elevated Plus Maze test - arm length value
Tags:
Designation:
arm length value
Tags:
Preferred Question Text
Designation:
Elevated Plus Maze test - arm width value
Tags:
Designation:
arm width value
Tags:
Preferred Question Text
Designations:
Definition:
Value of length maze arms (in centimeters), as part of Elevated Plus Maze test
Tags:
Definition:
Value of arm width (in centimeters), as part of Elevated Plus Maze test
Tags:
Short Description,Definition
Reference Documents:
ID:
Title:
A review of the validity and variability of the elevated plus-maze as an animal model of anxiety.
URI:
https://www.ncbi.nlm.nih.gov/pubmed/?term=8728535
Provider Org:
Language Code:
en-us
Document:
Despite or possibly by virtue of the fact that it is one of the most commonly used animal models of anxiety the Elevated Plus-Maze (EPM) results in a wide range of, often contradictory, results following pharmacological experiments. The responses from a questionnaire distributed to 65 groups that have published studies using the EPM in the past 3 years has, along with reference to published reports, enabled some conclusions regarding the influencing factors to be drawn. Some evidence for differential sensitivities between strains exists, with albino rats being more sensitive to the anxiolytic effects of 5-HT3 receptor antagonists and 5-HT1A receptor agonists than pigmented animals. Most important, however, is the manipulation of the animals prior to testing and the aversiveness of the test conditions themselves. Stressing animals before testing (e.g., by moving from holding to test room) or using more aversive test conditions (e.g., elevated light levels) increases sensitivity to potential anxiolytics. Animals that are habituated to gentle handling or tested in less aversive conditions (e.g., EPM with ledges) show reduced likelihood of anxiolytic responses with administration of 5-HT3 antagonists, 5-HT1A agonists, and benzodiazepines.
ID:
Title:
Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety.
URI:
https://www.ncbi.nlm.nih.gov/pubmed/?term=7862931
Provider Org:
Language Code:
en-us
Document:
The elevated "zero-maze" is a modification of the elevated plus-maze model of anxiety in rats which incorporates both traditional and novel ethological measures in the analysis of drug effects. The novel design comprises an elevated annular platform with two opposite enclosed quadrants and two open, removing any ambiguity in interpretation of time spent on the central square of the traditional design and allowing uninterrupted exploration. Using this model, the reference benzodiazepine anxiolytics, diazepam (0.125-0.5 mg/kg) and chlordiazepoxide (0.5-2.0 mg/kg) significantly increased the percentage of time spent in the open quadrants (% TO) and the frequency of head dips over the edge of the platform (HDIPS), and reduced the frequency of stretched attend postures (SAP) from the closed to open quadrants. In contrast, the anxiogenic drug m-chlorophenyl-piperazine (mCPP; 0.25-1.0 mg/kg) induced the opposite effects, decreasing %TO and HDIPS, and increasing SAP. The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.001-0.1 mg/kg) had no effects on either %TO or HDIPS, but did decrease SAP at 0.01 mg/kg although not at higher or lower doses. Similarly, the 5-HT3 receptor antagonist, ondansetron (0.0001-1.0 mg/kg) decreased SAP and increased %TO at 0.01 mg/kg, but not at other doses. The present data suggest that a combination of the novel "zero-maze" design and a detailed ethological analysis provides a sensitive model for the detection of anxiolytic/anxiogenic drug action.
ID:
Title:
Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety.